MX2022015813A - 2-amino-3-fluoro-but-3-enamidas macrociclicas como inhibidores de mcl-1. - Google Patents

2-amino-3-fluoro-but-3-enamidas macrociclicas como inhibidores de mcl-1.

Info

Publication number
MX2022015813A
MX2022015813A MX2022015813A MX2022015813A MX2022015813A MX 2022015813 A MX2022015813 A MX 2022015813A MX 2022015813 A MX2022015813 A MX 2022015813A MX 2022015813 A MX2022015813 A MX 2022015813A MX 2022015813 A MX2022015813 A MX 2022015813A
Authority
MX
Mexico
Prior art keywords
mcl
inhibitors
enamides
macrocyclic
fluoro
Prior art date
Application number
MX2022015813A
Other languages
English (en)
Inventor
Gaston Stanislas Marcella Diels
Frederik Jan Rita Rombouts
Soufyan Jerhaoui
Michel Surkyn
Matthieu Dominique Jouffroy
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2022015813A publication Critical patent/MX2022015813A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/16—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se relaciona con agentes farmacéuticos útiles para terapia y/o profilaxis en un sujeto, composición farmacéutica que comprende tales compuestos (Fórmula (I)) y su uso como inhibidores de MCL-1, útiles para tratar enfermedades tales como cáncer.
MX2022015813A 2020-06-10 2021-06-09 2-amino-3-fluoro-but-3-enamidas macrociclicas como inhibidores de mcl-1. MX2022015813A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20179237 2020-06-10
PCT/EP2021/065483 WO2021250102A1 (en) 2020-06-10 2021-06-09 Macrocyclic 2-amino-3-fluoro-but-3-enamides as inhibitors of mcl-1

Publications (1)

Publication Number Publication Date
MX2022015813A true MX2022015813A (es) 2023-01-24

Family

ID=71083532

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015813A MX2022015813A (es) 2020-06-10 2021-06-09 2-amino-3-fluoro-but-3-enamidas macrociclicas como inhibidores de mcl-1.

Country Status (10)

Country Link
US (1) US20230219906A1 (es)
EP (1) EP4165050A1 (es)
JP (1) JP2023528965A (es)
KR (1) KR20230023008A (es)
CN (1) CN115698023A (es)
AU (1) AU2021288987A1 (es)
BR (1) BR112022025117A2 (es)
CA (1) CA3180387A1 (es)
MX (1) MX2022015813A (es)
WO (1) WO2021250102A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020012137A (es) 2018-05-14 2021-01-29 Gilead Sciences Inc Inhibidores de mcl-1.
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
US11325891B2 (en) 2019-11-26 2022-05-10 Gilead Sciences, Inc. Processes and intermediates for preparing MCL1 inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3474B1 (ar) 2014-08-29 2020-07-05 Amgen Inc مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1
WO2017147410A1 (en) * 2016-02-25 2017-08-31 Amgen Inc. Compounds that inhibit mcl-1 protein
JP6453507B2 (ja) * 2017-03-30 2019-01-16 アムジエン・インコーポレーテツド Ｍｃｌ−１タンパク質を阻害する化合物
EP3668878A1 (en) 2017-08-18 2020-06-24 Amgen Inc. Compounds that inhibit mcl-1 protein
EP3676270A1 (en) * 2017-08-29 2020-07-08 Amgen Inc. Macrocyclic compounds that inhibit mcl-1 protein
MA54985A (fr) 2018-03-05 2021-12-29 Amgen Inc Pharmacophores d'acide alpha-hydroxy phénylacétique ou antagonistes de la protéine bio-isostère mcl-1
MX2020012137A (es) 2018-05-14 2021-01-29 Gilead Sciences Inc Inhibidores de mcl-1.
JP2022506973A (ja) 2018-11-09 2022-01-17 プレリュード セラピューティクス，インコーポレイティド 骨髄性細胞白血病－１（ｍｃｌ－１）タンパク質の阻害剤としてのスピロ－スルホンアミド誘導体
EP3771469A1 (en) 2019-07-30 2021-02-03 Amgen, Inc Formulations and dosages for administering a compound that inhibits mcl1 protein

Also Published As

Publication number Publication date
WO2021250102A1 (en) 2021-12-16
US20230219906A1 (en) 2023-07-13
CA3180387A1 (en) 2021-12-16
JP2023528965A (ja) 2023-07-06
AU2021288987A1 (en) 2023-02-09
KR20230023008A (ko) 2023-02-16
BR112022025117A2 (pt) 2022-12-27
EP4165050A1 (en) 2023-04-19
CN115698023A (zh) 2023-02-03

Similar Documents

Publication Publication Date Title
MX2022000390A (es) Derivados macrociclicos espirociclicos como inhibidores de mcl-1.
MX2022015813A (es) 2-amino-3-fluoro-but-3-enamidas macrociclicas como inhibidores de mcl-1.
MX2021006026A (es) Pirimidina y derivado heterociclico de nitrogeno de cinco miembros, metodo de preparacion y usos medicos de los mismos.
MX2021015770A (es) Inhibidores macrociclicos de mcl-1.
MX2023000438A (es) Eter macrociclico que contiene derivados de indol como inhibidores de mcl-1.
ZA202109010B (en) Compounds and methods for the treatment of covid-19
CR20230310A (es) Inhibidores de prmt5
MX2020006219A (es) Derivados de 1-piperidinocarbonilmetil)-2-oxopiperazina para tratar cancer.
PH12018501567A1 (en) New substituted cyanoindoline derivatives as nik inhibitors
SG10201810401RA (en) Pharmaceutical combinations for treating cancer
MX2021012501A (es) Inhibidores de complejo represivo polycomb 2 (prc2).
MX2019006843A (es) Inhibidor de cdk4/6.
MX2021006156A (es) Compuestos utiles en la terapia para el vih.
ZA202201364B (en) Deuterated compounds for use in the treatment of cancer
MX2023009222A (es) Inhibidores tricíclicos-amido-bicíclicos de prmt5.
MX2019014665A (es) Nuevos derivados de azaindolina sustituida como inhibidores de nik.
MX2022006180A (es) Derivados macrociclicos de sulfonilo como inhibidores de mcl-1.
MX2022006179A (es) Derivados macrociclicos de indol como inhibidores de mcl-1.
MX2023007297A (es) 3-fluoro-but-3-enamidas ramificadas macrociclicas como inhibidores de mcl-1.
MX2022015005A (es) Derivados de 7-pirazol-5-il-indol macrociclicos como inhibidores de mcl-1.
MX2023003516A (es) Inhibidores no covalentes de la cinasa dependiente de ciclina 7 (cdk7).
ZA202201499B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
MX2022010299A (es) Derivados macrocíclicos de indol como inhibidores de mcl-1.
MX2022011565A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2023007291A (es) Derivados de 4-(pirazol-5-il)-indol macrociclicos ramificados como inhibidores de mcl-1.